Skin & Hair · Copper tripeptide · Compounded 503A
AHK-Cu: the copper peptide built for hair.
AHK-Cu (alanyl-histidyl-lysine bound to copper) is a smaller, hair-targeted cousin of GHK-Cu. In dermatology research it stimulates dermal papilla cells, promotes follicular vascularization, and extends the hair-growth (anagen) phase — making it one of the most studied non-minoxidil peptide approaches to hair density.
What AHK-Cu is
AHK-Cu is the tripeptide alanyl-histidyl-lysine complexed with a copper(II) ion. It was developed alongside GHK-Cu by Loren Pickart and is the hair-focused member of the copper-peptide family.
Where GHK-Cu skews toward skin remodeling and anti-aging, AHK-Cu binds preferentially to receptors on the dermal papilla — the mesenchymal cell population at the base of each hair follicle that controls follicle cycling.
Clinically it is delivered as a topical scalp serum or as microinjected mesotherapy in physician offices. Compounded 503A formulations are typical in the U.S.
How it works
Copper is a required cofactor for lysyl oxidase, which crosslinks collagen and elastin in the perifollicular dermis — the structural scaffold every healthy follicle depends on. AHK-Cu acts as a delivery vehicle that drops copper directly onto papilla cells.
In cell culture, AHK-Cu increases VEGF expression in dermal papilla cells, which improves perifollicular microcirculation. Better blood supply means better delivery of oxygen, nutrients, and growth factors to the follicle bulb.
It also extends the anagen (growth) phase of the hair cycle and delays the catagen transition — translating to longer, thicker terminal hairs over successive cycles.
What patients use it for
Anagen-phase extension
Lengthens the active growth phase of each follicle, allowing hairs to reach greater length and diameter before shedding.
Perifollicular microcirculation
Upregulates VEGF in dermal papilla, increasing capillary density around follicle bulbs.
Non-hormonal mechanism
Unlike finasteride or dutasteride, AHK-Cu does not act on DHT — making it suitable for women, men avoiding 5-AR inhibition, and post-menopausal patients.
Stacks with minoxidil
Different mechanism than minoxidil (potassium-channel opener) — many dermatologists pair them for additive effect.
Evidence summary
Pyo HK et al. (Biological & Pharmaceutical Bulletin, 2007) demonstrated AHK-Cu's stimulation of hair follicle cells and VEGF upregulation in vitro.
Pickart L, Margolina A (International Journal of Molecular Sciences, 2018) reviewed copper-peptide biology including AHK-Cu hair-follicle effects.
Direct human RCT evidence for AHK-Cu monotherapy is limited; most clinical data is from peptide-blend mesotherapy or topical cosmeceutical formulations.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Most commonly topical scalp serum (daily) or intradermal mesotherapy injections (every 1–4 weeks for a 3–6 month induction).
Visible density and shedding changes typically take 3–6 months — full hair cycle duration.
Compounded by licensed 503A pharmacies under physician prescription.
Safety and contraindications
Generally well tolerated topically. Transient scalp tingling, mild redness, or pigment changes at injection sites are possible.
Contraindications: active scalp infection, copper allergy, Wilson's disease, pregnancy, lactation.
Not FDA-approved for hair loss — compounded use only under physician supervision.
Who it's typically considered for
- Women with diffuse thinning or post-menopausal hair density loss
- Men avoiding or intolerant of finasteride
- Patients pairing with minoxidil, GHK-Cu, or PRP for stacked protocols
- Patients with early-to-moderate androgenic or telogen-effluvium pattern hair loss
Frequently asked questions
AHK-Cu vs GHK-Cu — which?
GHK-Cu is broader (skin remodeling, wound healing, anti-aging). AHK-Cu is more selective for hair follicle stimulation. Many protocols use them together — GHK-Cu for scalp dermis quality, AHK-Cu for follicle cycling.
Does AHK-Cu work for women?
Yes — its non-hormonal mechanism makes it well-suited for female-pattern hair loss, post-menopausal thinning, and telogen effluvium.
Can I use it with minoxidil?
Yes — different mechanism. Many dermatology protocols layer them for additive density gains.
Will it work for total baldness?
No. Copper peptides stimulate existing follicles. They cannot regenerate follicles that have fully miniaturized or scarred (cicatricial alopecia).
How long until I see results?
Most patients see reduced shedding by 8–12 weeks and visible density changes by 4–6 months.
Is AHK-Cu FDA-approved?
No. The two FDA-approved hair-loss drugs are minoxidil and finasteride. AHK-Cu is a compounded peptide used off-label under physician supervision.
Sources
- Pyo HK et al. The effect of tripeptide-copper complex on human hair growth in vitro. Biol Pharm Bull (2007). — pubmed.ncbi.nlm.nih.gov/17541209
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. Int J Mol Sci (2018). — pubmed.ncbi.nlm.nih.gov/30021956
- Trüeb RM. Oxidative stress in ageing of hair. Int J Trichology (2009). — pubmed.ncbi.nlm.nih.gov/20805969
Considering AHK-Cu?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.